You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

18-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer

Version: 2 ID: 7-20 Version 2 oct 2012
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
Y.C. Ung, D.E. Maziak, J.A. Vanderveen, C.A. Smith, K. Gulenchyn, W.K. Evans, Lung Cancer Disease Site Group

Patient Population

Adult patients with lung cancer.

Research Question(s)

What is the role of 18-Fluorodeoxyglucose (18FDG) Positron Emission Tomography (PET) in:

  1. The diagnosis of solitary pulmonary nodules (SPN)?
  2. The staging of primary non-small cell lung cancer (NSCLC) at initial diagnosis?
  3. The staging of primary small cell lung cancer (SCLC)? Outcomes of interest include accuracy measures of imaging and the impact of PET on patient management and patient outcomes.
pdf download Summary (PDF) (77.83 Ko)
pdf download Full Report (PDF) (342.58 Ko)